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Skeletal muscleSIRT2 is primarily a cytoplasmic protein deacetylase and is abundantly expressed in metabolically active tissues
like adipocytes and brain. However, its role, if any, in regulating insulin signaling in skeletal muscle cells, is not
known.We have examined the role of SIRT2 in insulin-mediated glucose disposal in normal and insulin resistant
C2C12 skeletal muscle cells in vitro. SIRT2 was over expressed in insulin resistant skeletal muscle cells.
Pharmacological inhibition of SIRT2 increased insulin-stimulated glucose uptake and improved phosphorylation
of Akt and GSK3β in insulin resistant cells. Knockdown of endogenous SIRT2 and over expression of catalytically-
inactive SIRT2 mutant under insulin-resistant condition showed similar amelioration of insulin sensitivity. Our
results suggest that down-regulation of SIRT2 improved insulin sensitivity in skeletal muscle cells under
insulin-resistant condition. Previously it has been reported that down-regulation of SIRT1 and SIRT3 in C2C12
cells results in impairment of insulin signaling and induces insulin resistance. However, we have observed an
altogether different role of SIRT2 in skeletal muscle. This implicates a differential regulation of insulin resistance
by sirtuins which otherwise share a conserved catalytic domain. The study signiﬁcantly directs towards future
approaches in targeting inhibition of SIRT2 for therapeutic treatment of insulin resistance which is the major
risk factor in Type 2 diabetes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Mammalian sirtuins (SIRT 1–7) are NAD+ dependent protein
deacetylases, with a well-conserved catalytic domain. The variation in
their N- and C-terminus regions results in differential sub-cellular
localization and targets. Being dependent on NAD+, the activity of
these proteins is modulated with the changes in the level of NAD+/
NADH. They are expressed in all metabolically active tissues and play
a crucial role in regulating various cellular processes. SIRT1 is primarily
located in nucleus. It has been most elaborately studied for its crucial
role in regulation of insulin resistance [1–3]. Overexpression of SIRT1
in insulin-resistant C2C12 myotubes rescues the cells from impaired
insulin signaling [1]. SIRT1, therefore, is a possible therapeutic target
for treatment of Type-2 diabetes [4]. SIRT3, a major mitochondrial
deacetylase also plays a crucial role in regulation of insulin signaling.
Expression of SIRT3 decreases in diabetic mouse model. Knockdown of
SIRT3 in C2C12 cell line results in increased ROS levels, activation of
stress kinase JNK resulting in impaired insulin signaling [5]. In contrast
to this, SIRT6, anothermember of the sirtuin family, negatively regulates
insulin-mediated glucose uptake in skeletal muscle in vitro as well asin vivo [6]. No information is available about the role of SIRT2 in regulat-
ing insulin sensitivity.
SIRT2 is primarily a cytoplasmic protein deacetylase and is
abundantly expressed in metabolically active tissues like adipocytes
[7] and brain [8]. SIRT2 regulates adipocyte differentiation through
deacetylation of FOXO1 [7]. Knockdown of SIRT2 results in increased
insulin-mediated phosphorylation of FOXO1, thus restricting it to
cytoplasm. Expression of SIRT2 increases during caloric restriction and
oxidative stress. SIRT2 then interacts with FOXO3a to promote cell
death and overcome oxidative stress [9]. SIRT2 acts as a glucose sensor
in liver cells [10]. Pharmacological inhibition of SIRT2 by AGK2, a potent
and speciﬁc inhibitor of SIRT2, protects neurons from Huntingtin
cytotoxity in animal models of Huntington’s disease through modula-
tion in sterol metabolism [11].
Given the fact that SIRT2 plays critical role in metabolic activities in
liver, neurons and adipocytes and lack of report on the role of SIRT2 in
skeletal muscle, which is the major site for glucose disposal, we sought
to study the role of SIRT2 in insulin resistance and glucose disposal in
skeletal muscle in vitro. For this, we used chronic hyperinsulinemia
induced insulin-resistant model of skeletal muscle, previously generat-
ed and validated in our laboratory [12–15]. This model has been well-
studied for understanding the role of kinases and phosphatases in
insulin resistance [16,17]. In the present study, we observed a novel
role of SIRT2 in regulation of insulin signaling pathway under insulin-
resistant condition.
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Fig. 1. Effect of skeletal muscle insulin resistance on expression of SIRT2. C2C12 cells were
differentiated in serum free medium in absence (insulin sensitive; MF) or chronic
presence of 100 nM insulin (insulin resistant; MFI) for 3 days. Cell lysates were subjected
to Western immunoblotting and probed with anti-SIRT2 or anti-tubulin antibodies to
determine the expression of SIRT2 in MF and MFI condition. Bar represents relative
densitometric values of SIRT2 expression after normalizing with tubulin expression
(SIRT2/tubulin). Experiments were done thrice and a representative result is shown.
Values are mean ± SE. **p b 0.01 compared with lane 1. Open bar, MF; ﬁlled bar, MFI;
IB: immunoblot.
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2.1. Cell culture
C2C12 skeletal muscle cell lines were cultured as described
previously [12]. For differentiation, when the cells were 70% conﬂuent,
proliferation media was replaced with serum-free media containing
equal mixture of MCDB 201 and Ham's F-12 medium with chronic
presence of 100 nM insulin (MFI: insulin resistant) or without insulin
(MF: insulin sensitive) as reported previously [12]. Cells were
maintained in these media for 3 days with media replacement every
12 h. For inhibition of SIRT2, cells were treated with AGK2 during the
last 12 h of differentiation.
2.2. siRNA transfection
siRNA oligonucleotides against SIRT2 targeted sequence 5′-TGGCTA
AATCAAATTAACCTA-3′ were designed and synthesized by Qiagen
GmbH (Germany). C2C12 cells were transiently transfected with
SIRT2 speciﬁc and non-speciﬁc siRNA (400 nmol/l) using RNAifect
transfection reagent (Qiagen) in reduced-serum Opti-MEM media
(Gibco BRL, USA) according to the manufacturer's instructions, with
minor modiﬁcations.
2.3. Plasmid DNA transfection
The Flag-tagged SIRT2 Wild type and the Q130A deacetylase-
inactive mutant plasmids were a kind gift from Dr. Toren Finkel.
C2C12 skeletal muscle cells were transiently transfected with SIRT2-
wild type (SIRT2wt) and themutant plasmid (SIRT2Q130A) using Lipo-
fectamine 2000 transfection reagent (Invitrogen, USA) according to the
manufacturer's instructions, with minor modiﬁcations.
2.4. Cell lysis for immunoblotting and immunoprecipitaion
Differentiated C2C12 cells were stimulated with or without insulin
(100 nM) for 30 min. Cells were then lysed in lysis buffer containing
1% Triton X-100 as described previously [16] and equal amount of lysate
proteins were resolved by SDS-PAGE followed by immunoblotting. For
immunoprecipitation, 500 μg of protein was immunoprecipitated with
the appropriate antibody using Protein A/G-agarose beads (Santa Cruz
Biotechnology, USA). Immunoprecipitated proteins were resolved by
SDS-PAGE and transferred to nitrocellulose membranes for immuno-
blotting as reported previously [12]. Quantiﬁcation of Western immu-
noblots were performed using Quantity One 1-D analysis software
(Bio-Rad, USA) as described previously [16]. The relative values of the
samples were determined by giving an arbitrary value of 1.0 to the
respective control samples of each experiment, keeping the background
value as 0.
2.5. Glucose uptake
Glucose uptake was assayed using 2-NBDG as described earlier [18]
with minor modiﬁcations. Brieﬂy, media were removed and cells were
washed with a buffer containing NaCl 140 mM, KCl 5 mM, CaCl2 2.5
mM, MgSO4 1 mM, KH2PO4 1 mM, and HEPES 10 mM [pH 7.4] followed
by stimulation with or without 100 nM insulin for 30 min. Cells were
further incubated at 37 °C with 50 μM of 2-NBDG for 1 h, followed by
lysis in lysis buffer (sodium deoxycholate 1%, Nonidet P-40 1%, KCl
40 mM, and Tris 20 mM [pH 7.4]) for 10 min. Lysed cells were homog-
enized, followed by centrifugation at 16,000 × g for 15 min at 4 °C.
Fluorescence of aliquots from supernatants, containing equal amount
of proteinwasmeasured using Fluorescence Spectrometer LS55 (Perkin
Elmer, USA) at excitation and emission wavelengths of 485 nm and
535 nm, respectively.2.6. Statistical analysis
The data are expressed asmean±SE. For comparison of two groups,
p-values were calculated by two-tailed unpaired Student's t-test. In all
cases p b 0.05 was considered to be statistically signiﬁcant.
2.7. Reagents
Dulbecco's Modiﬁed Eagle Medium (DMEM), Fetal bovine serum
(FBS) and trypsin-EDTA,2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)
Amino)-2-Deoxyglucose (2-NBDG) was purchased from Life Technolo-
gies (USA). AGK2, Nutrient Mixture F-12 Ham, MCDB201 medium,
bovine albumin (cell culture grade), anti-SIRT2 antibody were from
Sigma Chemical Company (USA). Anti-phospho-Akt (Ser473), Anti-
Akt and Anti-phospho-GSK3β (Ser9), Anti-GSK-3β, were from Cell Sig-
naling Technology (USA). Antibodies against IR, IRS-1, α-tubulin,
phosphotyrosine, and anti-rabbit and anti-mouse IgG conjugated to
alkaline phosphatase were from Santa Cruz Biotechnology (USA).
Nitrocellulose membranes and TEMED were procured from Bio-Rad
Laboratories (USA). Recombinant insulin was purchased from
Calbiochem (USA). All the other reagents unless mentioned speciﬁcally
were either from Sigma Chemical Company or Amresco (USA).
3. Results
3.1. Effect of insulin resistance on expression of SIRT2 in differentiated
C2C12 skeletal muscle cells
To investigate whether SIRT2 has any association with insulin
resistance, we ﬁrst tested the expression of SIRT2 in C2C12 skeletal
muscle cells differentiated in insulin sensitive (MF) and insulin resistant
(MFI) conditions. The cellular lysates obtained from insulin sensitive
(MF) and resistant (MFI) were immunoblotted and probed with anti-
SIRT2 antibody. As shown in Fig. 1, SIRT2 expression was ~2.7
folds higher in insulin resistant cells as compared to the sensitive (p
b 0.01), suggesting increase in SIRT2 protein expression under
hyperinsulinemia-induced insulin resistant condition. This ﬁnding
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muscle cells.
3.2. Effect of SIRT2 inhibition on insulin stimulated deoxyglucose uptake
To further investigate the functional contribution of this altered
SIRT2 protein expression in skeletal muscle insulin resistance, glucose
uptake was measured in SIRT2 inhibited cells under insulin-sensitive
and insulin-resistant condition. C2C12 cells differentiated under MF or
MFI condition and treated with 50 μM of selective inhibitor of SIRT2,
AGK2, a vinyl nitrile [19] that binds the conserved pocket that partici-
pates in NAD+ binding and catalysis [20,21]. Cells were then stimulated
with or without insulin and uptake of glucose by cells was measured.
Insulin-mediated glucose uptake was signiﬁcantly impaired in cells dif-
ferentiated under chronic hyperinsulinemic conditions (MFI) as com-
pared to control MF cells (Fig. 2, lane 6 vs lane 2). Inhibition of SIRT2
under MFI condition improved insulin-stimulated glucose uptake by
97.8 ± 0.47% (Fig. 2, lane 6 vs lane 8, p b 0.01), resulting in comparable
glucose uptake as observed underMF condition (Fig. 2, lane 2 vs lane 8).
A small but signiﬁcant increase of 47.3 ± 0.32% in glucose uptake was
also observed in AGK2 treated MFI samples without insulin stimulation
(Fig. 2, lane 5 vs lane 7, p b 0.05). Surprisingly, there was an increase of
38.1 ± 0.45% in glucose uptake in MF condition without insulin stimu-
lation on AGK2 treatment (Fig. 2, lane 1 vs lane 3, p b 0.05), however in-
sulin stimulation did not increase glucose uptake further (Fig. 2, lane 2
vs lane 4). The result suggests that SIRT2 plays a key role in regulating
glucose disposal in skeletal muscle cells and inhibition of SIRT2 sensi-
tizes the cells to insulin under insulin-resistant condition.
3.3. Effect of SIRT2 inhibition on insulin signaling
Wenext investigated the plausiblemolecularmechanism for protec-
tion of cells from insulin resistance under SIRT2 inhibited condition. For
this, we tested the effect of SIRT2 downregulation on insulin signal
transduction cascade under normal (MF) and insulin resistant (MFI)
condition with or without insulin stimulation. A signiﬁcant reduction
of 76% was observed in insulin-stimulated Akt phosphorylation under
MFI condition (Fig. 3A, Panel A, lane 6 vs lane 2, p b 0.001). In accord
with the glucose uptake data, inhibition of SIRT2 alone improved0
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Fig. 2. Effect of inhibition of SIRT2 on glucose uptake. C2C12 cells were treated with or
without AGK2 (50 μM) were stimulated with (100 nM) or without insulin for 30 min,
followed by addition of 2-NBDG. Uptake of 2-NBDG was measured in 20 μg cell lysates.
Bar represents 2-NBDG ﬂuorescence. Experiments were done thrice and a representative
result is shown. Values are mean ± SE. *p b 0.05 compared with lane 1; $$p b 0.01
compared with lane 2; θp b 0.05 compared with lane 5; ##p b 0.01 compared with lane
6. Open bars, MF; ﬁlled bars, MFI; A.U.: arbitrary units.
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Fig. 3. Effect of inhibition of SIRT2 on insulin signaling. (A) C2C12 were treated with or
without AGK2 (50 μM) during the last 12 h of differentiation, followed by stimulation
with or without insulin (100 nM) for 30 min. Cell lysates were subjected to Western im-
munoblotting andprobedwith anti-phospho-Akt (ser473) or anti-Akt antibodies. Bar rep-
resents relative densitometric analysis of phospho-Akt after normalizing with Akt
expression (pAkt/Akt). (B) The effect of AGK2 on IRS-1 and GSK3β phosphorylation was
examined as in (A). Total cell lysates (500 μg) were immunoprecipitated with anti-IRS-1
(for Panels A and B) antibody, subjected to Western immunoblotting and probed with
anti-phosphotyrosine (Panel A), or anti-IRS1 (Panel B) antibodies. Cell lysates were sub-
jected to Western immunoblotting and probed with anti-phospho-GSK3β (Ser9) (Panel
C) or anti-GSK3β (Panel D) antibodies. Bar represents relative densitometric analysis of
phospho-GSK3β after normalizing with GSK3β expression (pGSK3β/GSK3β). Experi-
ments were done thrice and a representative result is shown. Values are mean ± SE.
###p b 0.001 compared with lane 1; θθθp b 0.001 compared with lane 2; **p b 0.01 com-
pared with lane 6; ##p b 0.01 compared with lane 1; θθp b 0.01 compared with lane 2;
*p b 0.05 compared with lane 6. Open bars, MF; ﬁlled bars, MFI. IB: immunoblot; IP:
immunoprecipitation.
1375A. Arora, C.S. Dey / Biochimica et Biophysica Acta 1842 (2014) 1372–1378insulin-stimulated Akt phosphorylation by ~1.4 folds under insulin-
resistant condition as compared to the respective untreated control
(Fig. 3A, Panel A, lane 6 vs lane 8 and bar diagram, p b 0.01). Under nor-
mal (MF) condition, insulin stimulation increased the phosphorylation
of Akt by ~5.5 folds (Fig. 3A, Panel A, lane 1 vs lane 2, p b 0.001) howev-
er, there was no further change in phosphorylation on AGK2 treatment
(Fig. 3A, Panel A, lane 2 vs lane 4). Expression of Akt remained the same
under all conditions tested (Fig. 3A, Panel B). The data suggests that
SIRT2 regulates insulin signaling pathway under insulin-resistant
condition.
To ascertain the role of SIRT2 in insulin signaling, phosphorylation of
IRS-1, the signalingmolecule upstream to Akt, and GSK3β, the immedi-
ate downstream target of Akt was tested. Insulin-stimulated tyrosine(A)
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Fig. 4. Effect ofmodulation of SIRT2 expression on insulin signaling and glucose uptake under in
serum free medium in chronic presence of 100 nM insulin (MFI) for 3 days and then stimulate
munoblotting and probedwith anti-SIRT2 or anti-FAK antibody (FAKwas used as an unrelated
SIRT2-siRNA-transfected cells. Bar represents relative densitometric values of SIRT2 expression
was measured in C2C12 cells were transfected with scramble or SIRT2 siRNA, followed by diffe
3 days. Uptake of 2-NBDG was measured in 20 μg cell lysates. Bar represents 2-NBDG ﬂuoresc
phospho-Akt (ser473) or anti-Akt antibodies. Bar represents relative densitometric analysis
were subjected to Western immunoblotting and probed with anti-phospho-GSK3β (Ser9) or
after normalizing with GSK3β expression (pGSK3β/GSK3β). All experiments were done thrice
lane 1; **p b 0.01 as compared to lane 2; *p b 0.05 as compared to lane 2. Filled bars, MFI. IB: iphosphorylation of IRS-1was impaired underMFI condition as compare
to respective MF sample (Fig. 3B, Panel A, lane 6 vs lane 2). However,
there was no further change in tyrosine phosphorylation of IRS-1 in
samples treated with AGK2 under MF or MFI condition (Fig. 3B, Panel
A, lane 4 vs lane 2 and lane 8 vs lane 6).
Further, insulin-mediated GSK3β phosphorylation was signiﬁcantly
impaired under MFI condition (Fig. 3B, Panel C and bar diagram,
lane 2 vs lane 6, p b 0.01). SIRT2 inhibition under such condition signif-
icantly restored its phosphorylation (increased by 28.8 ± 0.05%) on
insulin-stimulation (Fig. 3B, Panel C and bar diagram, lane 6 vs lane 8,
p b 0.05). There was no change in insulin-mediated GSK3β phosphory-
lation in insulin sensitive (MF) cellswith AGK2 treatment. Expression of
GSK3β remained the same under all conditions tested (Fig. 3B, Panel D).(B)
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1376 A. Arora, C.S. Dey / Biochimica et Biophysica Acta 1842 (2014) 1372–1378The data establishes that the increased glucose uptake due to SIRT2 in-
hibition is associated with concomitant increase in glycogen synthesis.
3.4. Knockdown of SIRT2 under insulin-resistant condition improves insulin
sensitivity
To validate the hypothesis that inhibition of SIRT2 improves insulin
sensitivity in skeletal muscle cells, C2C12 cells differentiated under
insulin-resistant (MFI) conditions, with or without insulin stimulation
were transfected with SIRT2 speciﬁc siRNA and silenced SIRT2 expres-
sion by 50% (Fig. 4A). We determined the effect of downregulation of
endogenous SIRT2 on insulin-stimulated deoxyglucose uptake under
the insulin resistant condition. Consistentwith theAGK2mediated inhi-
bition results, silencing of SIRT2 resulted in signiﬁcant increase (48.4 ±
0.33%) in insulin-stimulated glucose uptake under insulin resistant con-
dition (Fig. 4B, lane 4 vs. lane 2, p b 0.01).
We further examinedwhether thedepletion of this sirtuin could also
ameliorate the decreased insulin-mediated phosphorylation of Akt and
GSK3β. Knockdown of SIRT2 signiﬁcantly improved insulin-stimulated
Akt phosphorylation by 75.4 ± 0.24% (Fig. 4C, lane 4 vs lane 2 and bar
diagram, p b 0.05) and GSK3β phosphorylation by 37.9 ± 0.07
(Fig. 4D, lane 4 vs lane 2 and bar diagram, p b 0.05) under insulin-
resistant condition as compared to scramble-transfected controls. Ex-
pression of Akt (Fig. 4C, Panel B) and GSK3β (Fig. 4D, Panel B) remained
the same under all conditions tested. The data strongly supports that
SIRT2 negatively regulates insulin signaling in C2C12 skeletal muscle
cells.
3.5. Overexpression of catalytically-inactive SIRT2 mimics the effect of
pharmacological inhibition of SIRT2
To further conﬁrm that SIRT2 indeed regulates insulin resistance,
C2C12 cells were transfected with plasmid containing wild type
(SIRT2wt) and mutated (SIRT2Q130A) SIRT2 gene, followed by differ-
entiation in MFI condition that resulted in overexpression of both
SIRT2 (Fig. 5A, Panel A). We examined the effect of overexpression on
activity of insulin signaling molecules. Overexpression of catalytically-
inactive mutant resulted in amelioration of Akt phosphorylation on in-
sulin stimulation by 65.9 ± 0.9% (Fig. 5A, Panel B and bar diagram,
lane 2 vs lane 6, p b 0.01). Also, GSK3β phosphorylation improved by
50.3 ± 0.08% on insulin stimulation (Fig. 5B, upper panel and bar dia-
gram, lane 2 vs lane 6, p b 0.01). However, there was no further change
in phosphorylation of GSK3β on overexpression of wild type form.
There was no change in expression of AKT (Fig. 5A, Panel C) or GSK3β
(Fig. 5B, Panel B) under any condition. The result further proves that
SIRT2 negatively regulates insulin resistant C2C12 cells.
Further, we examined whether the over expression of catalytically-
deﬁcient mutant could also ameliorate the decreased insulin-stimulated
glucose uptake under the insulin resistant condition. Consistent with
the above results, overexpression of catalyticmutant SIRT2 led to a signif-
icant enhancement 83.6 ± 0.18% of insulin-stimulated glucose uptake
under MFI condition (Fig. 5C, lane 2 vs. lane 6, p b 0.01). However,Fig. 5.C2C12 cellswere transfectedwith SIRT2wt andQ130Amutant plasmid. Transfected
cells were differentiated in serum free medium containing chronic presence of 100 nM
insulin (MFI) for 3 days, followed by stimulation with or without insulin for 30 min and
cell lysis. (A) Lysate was subjected to Western immunoblotting and probed with anti-
SIRT2 antibody (Panel A), anti phospho-Akt (Ser473, Panel B), anti Akt (Panel C). Bar
represents relative densitometric values of pAkt after normalizing with Akt expression
(pAkt/Akt). (B) Lysate was subjected to Western immunoblotting and probed with anti-
pGSK3β antibody (upper panel), anti-GSK3β (lower panel) as in (A). Bar diagram
representing relative densitometric values of pGSK3β (Ser-9) after normalizing with
GSK3β expression (pGSK3β/GSK3β). (C) Insulin-stimulated 2-NBDG uptake was
measured in plasmid DNA transfected cells differentiated in serum free medium
containing chronic presence of 100 nM insulin (MFI) for 3 days. Uptake of 2-NBDG was
measured in 20 μg cell lysates. Bar represents 2-NBDG ﬂuorescence. All experiments
were done thrice and a representative result is shown. Values are mean ± SE. **p b 0.01
compared with lane 2. Filled bars, MFI. IB: immunoblot, A.U.: arbitrary units.
1377A. Arora, C.S. Dey / Biochimica et Biophysica Acta 1842 (2014) 1372–1378there was no further change in glucose disposal in insulin-resistant
C2C12 cells on overexpression of wild type SIRT2 (Fig. 5C, lane 2 vs.
lane 4). Results conclusively prove that SIRT2 negatively regulates insulin
resistance in C2C12 skeletal muscle cells.
Overall, these results suggest that SIRT2 plays a key role in regulating
glucose disposal and glycogen synthesis under insulin resistant condi-
tion in skeletal muscle cells by suppressing phosphorylation of Akt,
GSK3β and subsequently glucose uptake. Downregulation of SIRT2
under such conditions sensitizes the cells to insulin.
4. Discussion
In the present study, we have identiﬁed the role of SIRT2 in insulin
resistance in skeletal muscle cells. Expression of SIRT2 increases signiﬁ-
cantly when the cells are differentiated under chronic hyperinsulinemic
condition. Under such conditions, inhibition of SIRT2 either by AGK2
treatment or siRNA mediated knockdown improved insulin sensitivity
with signiﬁcant amelioration of insulin-stimulated uptake of glucose
by the cells. This observation was supported by data obtained from
over-expression of catalytically inactive mutant of SIRT2. Themolecular
mechanism for insulin sensitization on SIRT2 inhibition involved
insulin-mediated modulation of Akt and GSK3β activity. Interestingly,
we found that modulation of SIRT2 activity under insulin-sensitive con-
dition did not interfere with insulin action as there was no change in
insulin-mediated glucose disposal and Akt and GSK3β activity on
AGK2 treatment. This clearly indicates that SIRT2 acts as a key compo-
nent of a signaling network required to maintain the state of insulin re-
sistance and downregulation of SIRT2 improves insulin sensitivity
under such condition. The increased level of endogenous SIRT2 under
chronic hyperinsulinemic condition was sufﬁcient to maintain insulin
resistance and hence exogenous expression of wild-type SIRT2 did not
further aggravate this condition.
A recent study by Choi et al. [22] suggests that ERK1/2 interacts with
SIRT2 in HEK293 cells and regulates SIRT2 protein level. Also, ERK1/2
signaling is deregulated in insulin-resistant condition in skeletal muscle
cells and targeting ERK1/2 is proposed to be of potential therapeutic ap-
plication for treatment of insulin resistance [23]. Therefore, to under-
stand the increased expression of SIRT2 under insulin resistant
condition (Fig. 1A),we immunoprecipitated SIRT2with anti-ERK1/2 an-
tibody and vice versa in MF andMFI conditions. However, under our ex-
perimental conditions we did not observe any interaction between
SIRT2 with ERK1/2 under normal or hyperinsulinemic condition (data
not shown). Therefore the precise reason for an increased expression
of SIRT2 under insulin-resistant condition remains to be clariﬁed.
We observed that SIRT2 affects insulin signaling downstream to IRS-
1 as there was no change in tyrosine phosphorylation of IRS-1 on inhi-
bition of SIRT2 in C2C12 cells (Fig. 1C, Panel A). IRS-1-independent
Akt phosphorylation and subsequently glucose uptake have been previ-
ously reported in L6 skeletal muscle cell line [24].We also observed that
inhibition of SIRT2 enhanced glucose uptake in cells even without insu-
lin stimulation (Fig. 1D, lane 3 vs lane 1 and lane 7 vs lane 5; Fig. 2D, lane
3 vs lane 1). A plausible explanation could be an increase in the activity
of insulin-independent glucose transporter GLUT1 on inhibition of
SIRT2. Earlier, Xiao et al. [6] have shown that knockdown of SIRT6 in
C2C12 skeletal muscle cells results in signiﬁcant increase in expression
and membrane translocation of GLUT1, which was perhaps responsible
for increased uptake of glucose at the basal level.
SIRT2 directly interacts and deacetylates Akt which subsequently af-
fects glycogen synthase kinase-3β-catenin signaling pathway to regulate
motility of hepatocellular carcinoma cells [25]. Besides, SIRT1 directly in-
teracts and deacetylates Akt on stimulation with growth factors [26].
Deacetylation of Akt by SIRT1 thus enhances its binding to PIP3 andmem-
brane localization, thereby activating Akt. Recently, SIRT2 has been iden-
tiﬁed as the major interacting partner of AKT in insulin-responsive HEK-
293T cells [27]. To understand whether a direct interaction between
SIRT2 and Akt is responsible for change in insulin sensitivity under ourexperimental conditions, we immunoprecipitated SIRT2 with anti-Akt
antibody and vice versa, however,wedid not observe any such interaction
between Akt and SIRT2 (data not shown). Similar to Ramakrishnan et al.
[27],we also did not observe any change in acetylation of Akt inMForMFI
with or without insulin stimulation (data not shown). One possible rea-
son for this could be tissue-dependent interactions of sirtuins. For exam-
ple, SIRT1 interacts and deacetylates histone H3 to regulate insulin
sensitivity in C2C12 myotubes [1]. However, in adipocytes, SIRT1 targets
NF-κB deacetylation to improve insulin sensitivity [2]. In hepatocytes,
SIRT1 interactswith nuclear respiratory factor-1 (NRF-1) to regulate insu-
lin sensitivity [28]. In hypothalamic cells, SIRT1 interacts with IRS-1 to
regulate insulin sensitivity [29]. Therefore, tissue-speciﬁc functionality
happens to be a common mode of regulation by sirtuins. Further studies
are required to elucidate the precise target of SIRT2 by which it affects
Akt phosphorylation and subsequently insulin sensitivity under insulin-
resistant condition in skeletal muscle cells.
A recent study by Jiang et al. [10] proposes SIRT2 as a critical sensor
of cellular glucose level. In HEK293T cells, SIRT2 deacetylates and stabi-
lizes PEPCK1, an enzyme that catalyzes the rate-limiting step of gluco-
neogenesis. Since deregulation of gluconeogenesis is marker for
initiation of Type 2 diabetes and the critical role of SIRT2 is regulation
of this pathway, this study identiﬁes inhibition of SIRT2 as a therapeutic
approach against Type 2 diabetes. Another study shows that expression
of SIRT2 decreases in adipose tissue of diet-induced obese mice there-
fore resulting in deregulation of PGC1αmediatedmitochondrial energy
expenditure in adipocytes, resulting in glucose intolerance and insulin
resistance [30]. This identiﬁes SIRT2 as a positive regulator of metabolic
activities and augmentation of SIRT2 activity has been proposed as a
therapeutic approach for obesity and Type 2 diabetes. Our study adds
another perspective to the understanding of the role of SIRT2 in insulin
resistance. We propose that under normal condition SIRT2 does not in-
terfere with insulin action, however once the cells are resistant to insu-
lin action, SIRT2 negatively regulates insulin action and inhibition of
SIRT2 improves insulin sensitivity in skeletal muscle cells. Future stud-
ies might help in understanding the interplay between SIRT2 and
other sirtuins like SIRT1 and SIRT3 that positively regulate insulin sig-
naling in skeletal muscle.
In summary, we have unraveled a novel role of SIRT2 as a negative
regulator of insulin resistance in skeletal muscle cells. This ﬁnding es-
tablishes the importance of SIRT2 in pathophysiology of insulin resis-
tance which is of great signiﬁcance as insulin resistance is a major
cause for Type 2 diabetes. Approaches targeting inhibition of SIRT2
may be beneﬁcial for therapeutic treatment of Type 2 diabetes in the
near future.
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